21 CFR 516.34
§ 516.34 FDA recognition of exclusive marketing rights.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 516.34, § 516.34 FDA recognition of exclusive marketing rights, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87014
- Permanent ID
ys:prov:87014@1- SHA-256
b6cc492d1f6019ce5bb4983c4f67632b85cf50c68ac6de4523027715a9c5bcca
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) FDA will send the sponsor (or the permanent-resident U.S. agent, if applicable) timely written notice recognizing exclusive marketing rights when an application for a MUMS-designated drug has been conditionally approved or approved. The written notice will inform the sponsor of the requirements for maintaining MUMS-designated drug exclusive marketing rights for the full 7-year term. This notice will generally be contained in the letter conditionally approving or approving the application.
(b) When an application is conditionally approved or approved for a MUMS-designated drug that qualifies for exclusive marketing rights, FDA will publish this information in the Federal Register at the time of the conditional approval or approval. This notice will generally be contained in the notice of conditional approval or approval of the application.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.